BioXcel Therapeutics Inc. (NASDAQ: BTAI)
$1.24
+0.0200 ( +1.64% ) 745.7K
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Market Data
Open
$1.24
Previous close
$1.22
Volume
745.7K
Market cap
$47.10M
Day range
$1.17 - $1.47
52 week range
$1.04 - $12.21
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Sep 18, 2023 |
4 | Insider transactions | 1 | Sep 18, 2023 |
4 | Insider transactions | 1 | Sep 18, 2023 |
4 | Insider transactions | 1 | Sep 18, 2023 |
8-k | 8K-related | 12 | Sep 12, 2023 |
8-k | 8K-related | 12 | Sep 07, 2023 |
8-k | 8K-related | 12 | Aug 22, 2023 |
10-q | Quarterly Reports | 78 | Aug 14, 2023 |
8-k | 8K-related | 13 | Aug 14, 2023 |